Comparative studies on biodistribution and dosimetry showed longer half-lives in the tumor lesions for [177Lu]Lu-PSMA-617, but higher initial tumor uptake for [177Lu]Lu-PSMA I&T [23]. The gene discussed is FOLH1; the disease is neoplasm.